Download Free Haematologica The Hematology Journal Vol 79 N 1 Jan Feb 1994 Pavia Book in PDF and EPUB Free Download. You can read online Haematologica The Hematology Journal Vol 79 N 1 Jan Feb 1994 Pavia and write the review.

Includes section, "Recent book acquisitions" (varies: Recent United States publications) formerly published separately by the U.S. Army Medical Library.
This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.
This volume comprehensively reviews oncology in the precision medicine era of personalized care, latest developments in the field, and indications and clinical trials for the treatment of cancer with targeted therapies, immunotherapy, and epigenetic modulators. It thoroughly addresses concerns of various types of cancers including cancers of the head and neck, lung, colon, esophagus, bladder, pancreas, and breast; melanoma; multiple myeloma; hepatocellular carcinoma; renal cell carcinoma; and sarcomas. It is organized and written in a format that is easy to follow for both clinicians and non-clinical scientists interested in personalized medicine. Chapters cover the identification of the clinical problem and summary of recent findings, tumor biology and heterogeneity, genomics, examples of simple and complex cases, biological pathways, future clinical trials, and financial considerations. Oncology in the Precision Medicine Era: Value-Based Medicine will serve as a useful resource for medical oncologists and healthcare providers tailoring medicine to the needs of the individual patient, from prevention and diagnosis to treatment and follow up.
also occurs. New outbreaks of yellow fever have occurred in Colombia and Trinidad and new outbreaks of rift valley fever have occurred in Egypt. Chapter 6, Arenaviruses: The biochemical and physical properties have now been clar ified, and they show a remarkable uniformity in the various viruses constituting the group. The possibility that prenatal infection with LCM may result in hydrocephalus and chorioretinitis has been raised. Serologic surveys have suggested the existence of Lassa virus infection in Guinea, Central African Empire, Mali, Senegal, Cameroon, and Benin, in addition to earlier identification in Nigeria, Liberia, and Sierra Leone. Chapter 7, Coronaviruses: New studies have confirmed the important role of these viruses in common respiratory illnesses of children and adults. The viruses are now known to contain a single positive strand of RNA. About 50% of corona virus infections result in clinical illness. About 5% of common colds are caused by strain DC 43 in winter. Chapter 8, Cytomegalovirus: Sections on pathogenesis of CMV in relation to organ transplantation and mononucleosis, as well as sections on the risk and features of con genital infection and disease, have been expanded. There are encouraging preliminary results with a live CMV vaccine, but the questions of viral persistence and oncogenicity require further evaluation.
This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease. Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.